Health Catalyst Inc (HCAT)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $115.00M
Last updated: Nov 17, 2026 at 11:05 AM ET
Health Catalyst Inc (HCAT) Stock Forecast
Analysts expect Health Catalyst (HCAT) to earn -$0.04 per share in the fiscal year ending Dec 31, 2026, on revenue of $247.87M. Of 5 analysts, 1 rates the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.80, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 20% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 1 | 20.0% |
| Hold | 4 | 80.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 18.7%.
- Fiscal year ending Dec 31, 2026
- -$0.04
- EPS consensus, revenue $247.87M
- Fiscal year ending Dec 31, 2027
- -$0.02
- EPS consensus, revenue $201.62M
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.04 | -$0.06 to -$0.03 | 3 | $247.87M | $246.35M to $249.76M | 5 |
| Dec 31, 2027 | -$0.02 | -$0.12 to $0.10 | 4 | $201.62M | $182.52M to $211.50M | 5 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.04 | -$0.05 to -$0.03 | 7 | $51.77M | $48.96M to $54.81M | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 7 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 4 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.03.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.04 | -$0.04 | -$0.04 | -$0.05 | -$0.03 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.02 | $0.01 | $0.01 | $0.01 | $0.06 | N/A |
Frequently Asked Questions About HCAT
What is the HCAT stock forecast?
Consensus analyst estimates put Health Catalyst's EPS at -$0.04 for the fiscal year ending Dec 31, 2026, on revenue of $247.87M. The consensus rating from 5 analysts is Hold.
How do analysts rate HCAT stock?
Of 5 analysts covering Health Catalyst, 0 rate it Strong Buy, 1 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from HCAT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.04, with estimates from -$0.06 to -$0.03 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.02, with estimates from -$0.12 to $0.10 from 4 analysts.
What revenue do analysts expect from Health Catalyst next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $247.87M, with estimates from $246.35M to $249.76M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $201.62M, with estimates from $182.52M to $211.50M.
How many analysts cover HCAT?
5 analysts rate Health Catalyst stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HCAT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors